Exclusive Interview: Dr. William A. Carter, CEO. Hemispherx Biopharma, Inc. (AMEX:HEB)

Print E-mail
By M.E.Garza   
Friday, 12 June 2009 20:48

Dr.William A. Carter, the CEO of Hemispherx Biopharma shares his thoughts on the FDA delay, the flu pandemic and the future of his company. Late in the interview he also answers questions submitted to us by our readers. Certainly, the interview is filled with candid revelations and interesting nuggets of new information.

Warning: Due To Heavy Traffic And Length, The Screen May Not Load For A Few Seconds. Please Be Patient.
We also have an alternate feed available if you find that this feed is slow to load.

TRT: Approximately 45 Minutes







BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 
BioMedReports You may have billions and billions of good reasons for being unfit http://t.co/gr0UHAyTbU
8hreplyretweetfavorite
BioMedReports Kamada Announces Significantly Improved Infusion Rate for Glassia®; Celgene Acquires Late-Stage Product for Cr... http://t.co/Fir0Vzekc9
8hreplyretweetfavorite
BioMedReports Healthcare Review: Cesca Therapeutics, RTI Surgical, Amedisys, Celgene, Celgene: U.S. stocks rose, with the St... http://t.co/owMF3qezPA
11hreplyretweetfavorite
navigation
Benzinga.com supporter Seeking Alpha Certified